Literature DB >> 31677684

Ethical Considerations for Mechanical Support.

Darryl Abrams1, J Randall Curtis2, Kenneth M Prager3, A Reshad Garan4, Jonathan Hastie5, Daniel Brodie6.   

Abstract

Extracorporeal life support can support patients with severe forms of cardiac and respiratory failure. Uncertainty remains about its optimal use owing in large part to its resource-intensive nature and the high acuity illness in supported patients. Specific issues include the identification of patients most likely to benefit, the appropriate duration of support when prognosis is uncertain, and what to do when patients become dependent on extracorporeal life support but no longer have hope for recovery or transplantation. Careful deliberation of ethical principles and potential dilemmas should be made when considering the use of extracorporeal life support in advanced cardiopulmonary failure.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bridge to nowhere; ECMO; Ethics; Extracorporeal life support; Withdrawal of life support

Mesh:

Year:  2019        PMID: 31677684     DOI: 10.1016/j.anclin.2019.08.001

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  2 in total

Review 1.  Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.

Authors:  Kollengode Ramanathan; David Antognini; Alain Combes; Matthew Paden; Bishoy Zakhary; Mark Ogino; Graeme MacLaren; Daniel Brodie; Kiran Shekar
Journal:  Lancet Respir Med       Date:  2020-03-20       Impact factor: 30.700

Review 2.  Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications.

Authors:  Arthur S Slutsky; Alain Combes; Daniel Brodie; Darryl Abrams; Graeme MacLaren; Roberto Lorusso; Susanna Price; Demetris Yannopoulos; Leen Vercaemst; Jan Bělohlávek; Fabio S Taccone; Nadia Aissaoui; Kiran Shekar; A Reshad Garan; Nir Uriel; Joseph E Tonna; Jae Seung Jung; Koji Takeda; Yih-Sharng Chen
Journal:  Intensive Care Med       Date:  2021-09-10       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.